We are live on ! Find out more
CP

Caligan Partners Portfolio holdings

AUM $1.5B
1-Year Est. Return 518.95%
This Fund
S&P 500
This Quarter Est. Return
+17.43%
1 Year Est. Return
+518.95%
3 Year Est. Return
+1,728.44%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$315M
AUM Growth
-$113M
Cap. Flow
-$140M
Cap. Flow %
-44.41%
Top 10 Hldgs %
98.4%
Holding
13
New
–
Increased
5
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
YMAB
Y-mAbs Therapeutics
YMAB
+$7.77M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$2.95M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$2.85M
4
EOLS icon
Evolus
EOLS
+$359K
5
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$156K

Top Sells

Rank Stock Value
1
ALIM
Alimera Sciences
ALIM
+$93.6M
2
LQDA icon
Liquidia Corp
LQDA
+$24.5M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$15.3M
4
VRNA
Verona Pharma
VRNA
+$10M
5
ENTA icon
Enanta Pharmaceuticals
ENTA
+$9.42M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LQDA icon
1
Liquidia Corp
LQDA
$7.72B
$81.2M 25.73%
8,118,592
-2,242,353
-22% -$24.5M
VRNA
2
DELISTED
Verona Pharma
VRNA
$41.3M 13.1%
1,436,878
-406,878
-22% -$10M
EXEL icon
3
Exelixis
EXEL
$14.2B
$39.6M 12.55%
1,525,730
– –
EOLS icon
4
Evolus
EOLS
$410M
$35.5M 11.26%
2,193,488
+25,698
+1% +$359K
ANIK icon
5
Anika Therapeutics
ANIK
$202M
$35.4M 11.24%
1,435,130
-863
-0.1% -$22.4K
AGIO icon
6
Agios Pharmaceuticals
AGIO
$2.14B
$25.8M 8.16%
579,717
+65,006
+13% +$2.95M
BCRX icon
7
BioCryst Pharmaceuticals
BCRX
$2.48B
$19.6M 6.22%
2,583,585
-2,015,152
-44% -$15.3M
YMAB
8
DELISTED
Y-mAbs Therapeutics
YMAB
$15.7M 4.98%
1,195,253
+613,175
+105% +$7.77M
MLYS icon
9
Mineralys Therapeutics
MLYS
$2.38B
$11.9M 3.77%
981,155
+235,397
+32% +$2.85M
NBP
10
NovaBridge Biosciences American Depositary Shares
NBP
$202M
$4.34M 1.38%
3,499,330
+124,539
+4% +$156K
ENTA icon
11
Enanta Pharmaceuticals
ENTA
$367M
$3.34M 1.06%
322,453
-720,436
-69% -$9.42M
OTLK icon
12
Outlook Therapeutics
OTLK
$169M
$1.7M 0.54%
318,699
-181,301
-36% -$1.33M
ALIM
13
DELISTED
Alimera Sciences
ALIM
– –
-16,835,154
Closed -$93.6M

Similar funds

BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
JFGLC
Johnson Financial Group LLC (Colorado) Denver, Colorado $1.5B AUM 16.09% 1-Year Est. Return
AAM
Aureus Asset Management Boston, Massachusetts $1.5B AUM 20.3% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
RCW
Rheos Capital Works Tokyo, Japan $1.5B AUM 47.78% 1-Year Est. Return

Caligan Partners's Q3 2024 Portfolio in Review

As of Q3 2024, Caligan Partners held 13 positions worth $315M, down 26% from $428M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Caligan Partners withdrew a net $140M in Q3 2024, closing 1 position and reducing 6 holdings. Its most notable exit was Alimera Sciences, an estimated $93.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Caligan Partners added an estimated $7.77M to Y-mAbs Therapeutics.

  • Caligan Partners added most to Y-mAbs Therapeutics in Q3 2024, an estimated $7.77M increase.
  • Caligan Partners's biggest Q3 2024 reduction was Liquidia Corp, cutting an estimated $24.5M.
  • Caligan Partners fully exited Alimera Sciences in Q3 2024, selling an estimated $93.6M.
  • Caligan Partners's ten largest holdings make up 98% of its $315M portfolio in Q3 2024.
  • Caligan Partners opened 0 new positions and closed 1 in Q3 2024.
  • Caligan Partners's portfolio value fell 26% quarter-over-quarter to $315M.

Based on Caligan Partners's 13F filing for Q3 2024, filed 14 Nov 2024.